Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Bortezomib market france?
What is dabrafenib mesylate msn patent issue?
Drugpatentwatch trametinib?
Drugpatentwatch crizotinib?
Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?

Biosimilar lantus?

See the DrugPatentWatch profile for lantus

Biosimilar Lantus – what it is and what you should know

Item What it means
Lantus A brand‑name long‑acting insulin (insulin glargine) that gives a steady, basal insulin level for 24 h.
Biosimilar A drug that is highly similar to an already‑approved “reference” biologic (in this case, Lantus) in terms of quality, safety and efficacy. The FDA (or EMA, PMDA, etc.) requires extensive analytical, animal, and human studies to prove equivalence.
Common biosimilar name Basaglar (by Eli Lilly) is the most widely available U.S. biosimilar of Lantus. Other reference‑insulin glargines (like Lantus) are also on the market.

Why use a biosimilar?

Reason Explanation
Cost Biosimilars are generally 15‑30 % cheaper than the reference product, which can make basal insulin therapy more affordable for patients and health‑care systems.
Equivalence Clinical trials show that Basaglar, for example, produces the same glucose‑lowering effect and has a comparable safety profile to Lantus.
Supply Having multiple manufacturers reduces shortages.

What to expect if you’re switched to a biosimilar

Issue Key points
Efficacy Clinical data show similar glycemic control (HbA1c reduction, fasting glucose, etc.).
Safety / Hypoglycemia Rates of mild‑to‑moderate hypoglycemia are comparable. Severe hypoglycemia incidence is also similar.
Immunogenicity Incidence of anti‑insulin antibodies is very low and not clinically significant in most patients.
Administration Same dosing schedule: once daily (usually at bedtime) with a 100 U/mL prefilled pen.
Monitoring Continue your regular glucose checks, HbA1c monitoring, and report any new or worsening symptoms.

Practical tips for patients

  1. Talk to your provider – a change from Lantus to Basaglar (or another biosimilar) is usually a switch rather than an add‑on. Your clinician will confirm whether a direct switch is appropriate.
  2. Use the same pen type – biosimilar pens are designed to match the reference pen’s feel and dosing increments, so you typically don’t need to learn a new device.
  3. Watch for signs of hypoglycemia – symptoms (shakiness, sweating, confusion) are the same as with any insulin. If you notice anything unusual, contact your health‑care team right away.
  4. Keep records – track your glucose readings, insulin doses, and any side‑effects for your next appointment. This helps your provider fine‑tune therapy.
  5. Cost‑coverage – check with your insurer or pharmacy benefit manager. Many plans now list biosimilar insulins on the same tier as the reference product, but coverage details can vary.

Quick FAQ

Question Short answer
Is Basaglar exactly the same as Lantus? It’s “highly similar.” No clinically relevant differences in pharmacology have been shown.
Do I need to do a “titration” when I switch? Most protocols use a direct switch at the same dose. However, your clinician may recommend a brief titration period if you’re unsure.
Will my insurance cover the biosimilar? Many plans do. Contact your insurer for specific formulary status.
Is there a risk of increased hypoglycemia? Clinical trials show similar rates. Any changes in your personal risk profile (e.g., kidney function, other meds) should be discussed with your clinician.
What about other biosimilars? Lantus is insulin glargine; other biosimilars of glargine are available in various markets. In the U.S. only Basaglar is approved, but other countries may have additional options.

Bottom line

Biosimilars like Basaglar offer a cost‑effective, clinically equivalent alternative to Lantus for long‑acting insulin. They are approved only after rigorous testing to ensure no meaningful differences in safety or efficacy. If you’re considering a switch, discuss it with your diabetes educator or endocrinologist—they’ll help decide if a biosimilar is the right fit for you.



Other Questions About Lantus :

Lantus pricing? Lantus inj price? Cost of lantus? What year was lantus approved by the fda? How much does lantus cost without insurance? Inj lantus price? Lantus qiymeti?